Concord Biotech Ltd

Concord Biotech announced the successful completion of an ANVISA inspection conducted by the Brazilian Health Regulatory Agency at the company's API manufacturing facility in Limbasi. The inspection took place from 08 June to 12 June 2026, and was concluded successfully.

The inspection was carried out between 8 June and 12 June 2026 and concluded successfully, the company said in a regulatory filing. The company said, The successful completion of the ANVISA inspection marks a significant milestone in Concord Biotech's global growth journey. This achievement reinforces our commitment to the highest standards of quality and regulatory excellence while strengthening our global manufacturing and regulatory footprint. It also advances our international expansion strategy by enhancing access to one of the world's largest pharmaceutical markets and broadening the reach of our high-quality APIs across key geographies. Concord Biotech is an R&D-driven biopharma company that manufactures Active Pharmaceutical Ingredients (APIs) through fermentation & semi-synthetic processes and finished formulations. It has a presence in more than 70 countries worldwide. The company's consolidated net profit declined 36.75% to Rs 88.79 crore on a 24.15% drop in revenue from operations to Rs 326.07 crore in Q4 FY26 over Q4 FY25. Powered by Capital Market - Live

Concord Biotech has received approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Tofacitinib Tablets, 5 mg and 10 mg. Tofacitinib tablets are indicated for the treatment of adult patients with Moderately to severely active rheumatoid arthritis (RA), Active psoriatic arthritis (PsA), Active ankylosing spondylitis (AS), Moderately to severely active ulcerative colitis (UC), Active PsA, Active polyarticular course juvenile idiopathic arthritis (pcJIA). According to market estimates, the U.S. market for Tofacitinib Tablets both strengths put together is approximately US$ 500 million. The approval positions the Company to capitalize on these attractive market opportunities, enhance its product offerings, and support its long-term growth strategy across the U.S. and international markets.

Tofacitinib tablets are indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, and polyarticular-course juvenile idiopathic arthritis. According to market estimates, the US market size for Tofacitinib tablets across both strengths is approximately $500 million. The approval is expected to enable the company to tap this market opportunity, expand its product portfolio, and support its long-term growth strategy in the US and other international markets. Concord Biotech is an R&D-driven biopharma company that manufactures Active Pharmaceutical Ingredients (APIs) through fermentation & semi-synthetic processes and finished formulations. It has a presence in more than 70 countries worldwide. The company's consolidated net profit declined 36.75% to Rs 88.79 crore on a 24.15% drop in revenue from operations to Rs 326.07 crore in Q4 FY26 over Q4 FY25. Powered by Capital Market - Live

Mangalore Refinery And Petrochemicals Ltd, Cartrade Tech Ltd, IFCI Ltd, RHI Magnesita India Ltd are among the other stocks to see a surge in volumes on NSE today, 03 June 2026.Concord Biotech Ltd notched up volume of 53.35 lakh shares by 14:14 IST on NSE, a 14.12 fold spurt over two-week average daily volume of 3.78 lakh shares. The stock rose 3.74% to Rs.1,209.80. Volumes stood at 18.58 lakh shares in the last session.Mangalore Refinery And Petrochemicals Ltd witnessed volume of 225.12 lakh shares by 14:14 IST on NSE, a 7.07 times surge over two-week average daily volume of 31.86 lakh shares. The stock increased 4.34% to Rs.153.40. Volumes stood at 28.97 lakh shares in the last session.Cartrade Tech Ltd notched up volume of 26.83 lakh shares by 14:14 IST on NSE, a 5.18 fold spurt over two-week average daily volume of 5.18 lakh shares. The stock rose 8.55% to Rs.1,948.40. Volumes stood at 3.79 lakh shares in the last session.IFCI Ltd recorded volume of 2229.96 lakh shares by 14:14 IST on NSE, a 5.14 times surge over two-week average daily volume of 433.75 lakh shares. The stock gained 12.83% to Rs.80.83. Volumes stood at 1057.43 lakh shares in the last session.RHI Magnesita India Ltd recorded volume of 60.27 lakh shares by 14:14 IST on NSE, a 5.08 times surge over two-week average daily volume of 11.88 lakh shares. The stock gained 8.95% to Rs.375.50. Volumes stood at 29.11 lakh shares in the last session.Powered by Capital Market - Live

Divis Laboratories Ltd, Granules India Ltd, Mangalore Refinery And Petrochemicals Ltd, Alkyl Amines Chemicals Ltd are among the other stocks to see a surge in volumes on BSE today, 03 June 2026.Concord Biotech Ltd witnessed volume of 1.68 lakh shares by 10:46 IST on BSE, a 9.35 times surge over two-week average daily volume of 17948 shares. The stock increased 6.13% to Rs.1,238.30. Volumes stood at 74467 shares in the last session.Divis Laboratories Ltd saw volume of 1.78 lakh shares by 10:46 IST on BSE, a 7.15 fold spurt over two-week average daily volume of 24834 shares. The stock dropped 0.15% to Rs.6,518.50. Volumes stood at 16261 shares in the last session.Granules India Ltd clocked volume of 5.05 lakh shares by 10:46 IST on BSE, a 4.59 times surge over two-week average daily volume of 1.10 lakh shares. The stock gained 1.71% to Rs.790.10. Volumes stood at 30974 shares in the last session.Mangalore Refinery And Petrochemicals Ltd registered volume of 8.35 lakh shares by 10:46 IST on BSE, a 3.76 fold spurt over two-week average daily volume of 2.22 lakh shares. The stock rose 4.11% to Rs.153.25. Volumes stood at 1.53 lakh shares in the last session.Alkyl Amines Chemicals Ltd witnessed volume of 48669 shares by 10:46 IST on BSE, a 3.25 times surge over two-week average daily volume of 14986 shares. The stock increased 1.11% to Rs.1,806.40. Volumes stood at 84431 shares in the last session.Powered by Capital Market - Live

Mycophenolate mofetil is an antimetabolite immunosuppressant used to prevent organ rejection in adult and pediatric patients aged three months and older who have undergone kidney, heart, or liver transplants, in combination with other immunosuppressants. According to market estimates, the U.S. market for Mycophenolate Mofetil is approximately US$ 30 million. The approval positions the company to capitalize on these attractive market opportunities, enhance its product offerings, and support its long-term growth strategy across the U.S. and international markets. Concord Biotech is a R&D driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It has a presence in more than 70 countries worldwide. The company's consolidated net profit declined 36.75% to Rs 88.79 crore on 24.15% drop in revenue frm operations to Rs 326.07 crore in Q4 FY26 over Q4 FY25Powered by Capital Market - Live

Concord Biotech announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 7.55 per equity Share (i.e. 755%) , subject to the approval of the shareholders.

Net profit of Concord Biotech declined 36.75% to Rs 88.79 crore in the quarter ended March 2026 as against Rs 140.39 crore during the previous quarter ended March 2025. Sales declined 24.15% to Rs 326.08 crore in the quarter ended March 2026 as against Rs 429.88 crore during the previous quarter ended March 2025. For the full year,net profit declined 29.79% to Rs 260.91 crore in the year ended March 2026 as against Rs 371.64 crore during the previous year ended March 2025. Sales declined 12.10% to Rs 1054.89 crore in the year ended March 2026 as against Rs 1200.09 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales326.08429.88 -24 1054.891200.09 -12 OPM %36.2943.94 -34.8342.08 - PBDT133.62198.16 -33 422.39548.93 -23 PBT114.08183.54 -38 347.93494.55 -30 NP88.79140.39 -37 260.91371.64 -30 Powered by Capital Market - Live

Concord Biotech will hold a meeting of the Board of Directors of the Company on 29 May 2026.